Literature DB >> 26321629

Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy.

Tomoaki Higashiyama1, Yasuhiro Nishida2, Masahito Ohji3.   

Abstract

PURPOSE: To evaluate the changes of orbital tissue volumes and proptosis after methylprednisolone pulse therapy in thyroid-associated ophthalmopathy (TAO).
METHODS: The cross-sectional areas of orbital tissues and proptosis were measured with magnetic resonance imaging in 40 orbits of 20 patients with TAO before and after methylprednisolone pulse therapy. The volumes of the whole orbit, orbital fatty tissue, and extraocular muscles were calculated. The volumes and proptosis were compared before and after treatment using a paired t test.
RESULTS: Before treatment, the mean volumes were 33.0 ± 4.8 cm(3) in the whole orbit, 19.9 ± 4.1 cm(3) in the orbital fatty tissue, and 4.6 ± 1.2 cm(3) in the total extraocular muscles. After treatment, the mean volumes were 32.5 ± 4.4 cm(3) in the whole orbit, 19.9 ± 3.7 cm(3) in the orbital fatty tissue, and 4.0 ± 1.0 cm(3) in the total extraocular muscles. The mean volumes of the whole orbit (P = 0.17) and orbital fatty tissue (P = 0.82) were not significantly decreased after treatment, while the mean volume of total extraocular muscles was significantly decreased (P < 0.001). The mean proptosis value was 18.9 ± 2.8 mm before treatment and 18.6 ± 3.4 mm after treatment. The mean proptosis value was not significantly decreased after treatment (P = 0.30).
CONCLUSIONS: The volume of orbital fatty tissue seemed to be unchanged after methylprednisolone pulse therapy while that of total extraocular muscles was decreased. The proptosis value seemed to be unchanged after treatment.

Entities:  

Keywords:  Magnetic resonance imaging; Methylprednisolone pulse therapy; Proptosis; Thyroid-associated ophthalmopathy; Volume

Mesh:

Substances:

Year:  2015        PMID: 26321629     DOI: 10.1007/s10384-015-0410-4

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  19 in total

1.  Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.

Authors:  Kenji Ohtsuka; Akihiko Sato; Satoshi Kawaguchi; Masato Hashimoto; Yasuo Suzuki
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

2.  High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy.

Authors:  Ritva Kauppinen-Mäkelin; Anni Karma; Eeva Leinonen; Eliisa Löyttyniemi; Oili Salonen; Timo Sane; Kirsi Setälä; Jorma Viikari; Armin Heufelder; Matti Välimäki
Journal:  Acta Ophthalmol Scand       Date:  2002-06

3.  Significance of orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy.

Authors:  Yasuhiro Nishida; Suna Tian; Bengt Isberg; Osamu Hayashi; Leif Tallstedt; Gunnar Lennerstrand
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-06-20       Impact factor: 3.117

4.  Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.

Authors:  Seigo Tachibana; Tsukasa Murakami; Hitoshi Noguchi; Yasushi Noguchi; Akiko Nakashima; Yufuko Ohyabu; Shiro Noguchi
Journal:  Endocr J       Date:  2010-08-19       Impact factor: 2.349

5.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

Review 6.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

7.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

Review 8.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 9.  Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

Review 10.  Immune mechanisms in thyroid eye disease.

Authors:  Geniece M Lehmann; Steven E Feldon; Terry J Smith; Richard P Phipps
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

View more
  15 in total

1.  [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].

Authors:  Wei Jiang; Qiu-Yue Cai; Zhang-Fang Li; Zhi-Yi Chen; Yao-Sheng Luo; Shi-di Hu; Jie Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

2.  [A novel method for quantitative measurement of orbital fat volume based on magnetic resonance images].

Authors:  Qiu-Yue Cai; Zhi-Yi Chen; Wei Jiang; Yao-Sheng Luo; Zhang-Fang Li; Shi-di Hu; Jie Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

3.  Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy.

Authors:  Y Kaichi; K Tanitame; H Itakura; H Ohno; M Yoneda; Y Takahashi; Y Akiyama; K Awai
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

4.  Usefulness of two-point Dixon T2-weighted imaging in thyroid-associated ophthalmopathy: comparison with conventional fat saturation imaging in fat suppression quality and staging performance.

Authors:  Lu Chen; Hao Hu; Huan-Huan Chen; Wen Chen; Qian Wu; Fei-Yun Wu; Xiao-Quan Xu
Journal:  Br J Radiol       Date:  2020-12-22       Impact factor: 3.039

5.  Quantitative Analysis of Inflammation in Orbital Fat of Thyroid-associated Ophthalmopathy Using MRI Signal Intensity.

Authors:  Tomoaki Higashiyama; Maki Iwasa; Masahito Ohji
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

6.  Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy.

Authors:  Tomoaki Higashiyama; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2018-11-27

7.  Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging.

Authors:  Tomoaki Higashiyama; Takayuki Minamikawa; Masashi Kakinoki; Osamu Sawada; Masahito Ohji
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

8.  Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy.

Authors:  Yue-Yue Wang; Qian Wu; Lu Chen; Wen Chen; Tao Yang; Xiao-Quan Xu; Fei-Yun Wu; Hao Hu; Huan-Huan Chen
Journal:  Endocr Connect       Date:  2021-06-24       Impact factor: 3.335

9.  Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2016-04-20

10.  Extraocular muscle sampled volume in Graves' orbitopathy using 3-T fast spin-echo MRI with iterative decomposition of water and fat sequences.

Authors:  Ludovico M Garau; Daniele Guerrieri; Flaminia De Cristofaro; Alice Bruscolini; Giuseppe Panzironi
Journal:  Acta Radiol Open       Date:  2018-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.